Radiopharmaceuticals and Nanotechnology

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 25 February 2025 | Viewed by 1614

Special Issue Editors


E-Mail Website
Guest Editor
Medical Physics Department, Jules Bordet Institute, 90 Rue Meylemeersch, B-1070 Brussel, Belgium
Interests: radiobiology; nanomedicine; radiosensitizer; DNA damage; high-LET radiation
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Preclinical Radiotherapy and Radiobiology Research Team, PIRP, INSERM-1231, Centre Georges François Leclerc, Unicancer, 1 rue Pr Marion, 21079 Dijon, France
Interests: radiobiology; nanomedicine; radio-induced immune response; external radiotherapy; immunotherapy

Special Issue Information

Dear Colleagues,

Over the past decades, the development of nanomedicine has offered the possibility to exploit nanoscale materials for a wide range of applications, improving the diagnosis and treatment of serious diseases. Numerous proofs-of-concept and developments were recently published, opening up possibilities for targeted and personalized therapy, changing the paradigm of cancer treatment from the conventional local approach to a more systemic one. These promising results also raised some questions about the challenges of rapidly transitioning these technologies to the clinic and highlighted the need for multi-disciplinary teams that join forces.

In this special issue of Pharmaceuticals, we aim to provide exciting insights into state-of-the-art research as well as future developments in the field of nanotechnologies for radiation-based diagnosis and treatment. We invite transdisciplinary teams to submit papers (full research papers, short communications and review) covering a range of topics in the field including, but not limited to:

  • The design and synthesis of novel nanomaterials/tracers;
  • The use of nanotechnology for multi-modal applications including targeted drug delivery, imaging or radiation therapy;
  • Characterization and modelling of the pharmacokinetics/pharmacodynamics of radiopharmaceuticals and nano-objects;
  • New in vivo (pre)-clinical validations of nanomaterials and radiopharmaceuticals for the treatment of cancer and other diseases;
  • Nanotechnology-enhanced dosimetry of radiotherapy and radiopharmaceutical therapy.

Dr. Sébastien Penninckx
Dr. Céline Mirjolet
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiopharmaceutics
  • nanoparticle
  • radiation (external beam radiotherapy, nuclear medicine, brachytherapy, PET, SPECT, …)
  • theranostic
  • nanomedicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

21 pages, 3397 KiB  
Article
In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer
by Ayça Tunçel, Simone Maschauer, Olaf Prante and Fatma Yurt
Pharmaceuticals 2024, 17(6), 732; https://doi.org/10.3390/ph17060732 - 5 Jun 2024
Viewed by 1176
Abstract
This study assessed the effectiveness of a trastuzumab-targeted 177Lu-labeled mesoporous Carbon@Silica nanostructure (DOTA@TRA/MC@Si) for HER2-positive breast cancer treatment, focusing on its uptake, internalization, and efflux in breast cancer cells. The synthesized PEI-MC@Si nanocomposite was reacted with DOTA-NHS-ester, confirmed by the Arsenazo(III) assay. [...] Read more.
This study assessed the effectiveness of a trastuzumab-targeted 177Lu-labeled mesoporous Carbon@Silica nanostructure (DOTA@TRA/MC@Si) for HER2-positive breast cancer treatment, focusing on its uptake, internalization, and efflux in breast cancer cells. The synthesized PEI-MC@Si nanocomposite was reacted with DOTA-NHS-ester, confirmed by the Arsenazo(III) assay. Following this, TRA was conjugated to the DOTA@PEI-MC@Si for targeting. DOTA@PEI-MC@Si and DOTA@TRA/MC@Si nanocomposites were labeled with 177Lu, and their efficacy was evaluated through in vitro radiolabeling experiments. According to the results, the DOTA@TRA/MC@Si nanocomposite was successfully labeled with 177Lu, yielding a radiochemical yield of 93.0 ± 2.4%. In vitro studies revealed a higher uptake of the [177Lu]Lu-DOTA@TRA/MC@Si nanocomposite in HER2-positive SK-BR-3 cells (44.0 ± 4.6% after 24 h) compared to MDA-MB-231 cells (21.0 ± 2.3%). The IC50 values for TRA-dependent uptake in the SK-BR-3 and BT-474 cells were 0.9 µM and 1.3 µM, respectively, indicating affinity toward HER-2 receptor-expressing cells. The lipophilic distribution coefficients of the radiolabeled nanocomposites were determined to be 1.7 ± 0.3 for [177Lu]Lu-DOTA@TRA/MC@Si and 1.5 ± 0.2 for [177Lu]Lu-DOTA@PEI-MC@Si, suggesting sufficient passive transport through the cell membrane and increased accumulation in target tissues. The [177Lu]Lu-DOTA@TRA/MC@Si nanocomposite showed an uptake into HER2-positive cell lines, marking a valuable step toward the development of a nanoparticle-based therapeutic agent for an improved treatment strategy for HER2-positive breast cancer. Full article
(This article belongs to the Special Issue Radiopharmaceuticals and Nanotechnology)
Show Figures

Graphical abstract

Back to TopTop